{Reference Type}: Journal Article
{Title}: Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma.
{Author}: Maia-Silva D;Cunniff PJ;Schier AC;Skopelitis D;Trousdell MC;Moresco P;Gao Y;Kechejian V;He XY;Sahin Y;Wan L;Alpsoy A;Liverpool J;Krainer AR;Egeblad M;Spector DL;Fearon DT;Dos Santos CO;Taatjes DJ;Vakoc CR;
{Journal}: Nat Genet
{Volume}: 56
{Issue}: 7
{Year}: 2024 Jul 17
{Factor}: 41.307
{DOI}: 10.1038/s41588-024-01790-y
{Abstract}: The presence of basal lineage characteristics signifies hyperaggressive human adenocarcinomas of the breast, bladder and pancreas. However, the biochemical mechanisms that maintain this aberrant cell state are poorly understood. Here we performed marker-based genetic screens in search of factors needed to maintain basal identity in pancreatic ductal adenocarcinoma (PDAC). This approach revealed MED12 as a powerful regulator of the basal cell state in this disease. Using biochemical reconstitution and epigenomics, we show that MED12 carries out this function by bridging the transcription factor ΔNp63, a known master regulator of the basal lineage, with the Mediator complex to activate lineage-specific enhancer elements. Consistent with this finding, the growth of basal-like PDAC is hypersensitive to MED12 loss when compared to PDAC cells lacking basal characteristics. Taken together, our genetic screens have revealed a biochemical interaction that sustains basal identity in human cancer, which could serve as a target for tumor lineage-directed therapeutics.